Insulin costs and use by US Medicare beneficiaries after the inflation reduction act out-of-pocket cap
JAMA Network
About The Study:
The Medicare $35 insulin out-of-pocket cap implemented in 2023 decreased and stabilized insulin out-of-pocket cost, increasing insulin use for people with previously high out-of-pocket cost. These findings can inform the design of policies to boost insulin access among users with high out-of-pocket cost.
Corresponding Author: To contact the corresponding author, Rebecca Myerson, PhD, email Rebecca.myerson@emory.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2026.5975)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the 2026 American Diabetes Association’s Scientific Sessions.
Embed this link to provide your readers free access to the full-text article
Journal
JAMA
.jpg)
No comments:
Post a Comment